News

Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement

Hørsholm, Denmark – January 13, 2025 AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market. Under this collaboration, Cevidra will serve as the local...

Er-Kim and AFYX Therapeutics A/S announce distribution and sales collaboration

Hørsholm, Denmark – January 6, 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and distribute the...

AFYX Therapeutics A/S Secures DKK 25 million in Funding

Copenhagen, Denmark – December 19, 2024 AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical company specializing in reversed innovation and the repurposing of established pharmaceutical substances, has successfully raised DKK 25 million in its latest funding...

Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement

Er-Kim and AFYX Therapeutics A/S announce distribution and sales collaboration

AFYX Therapeutics A/S Secures DKK 25 million in Funding

Genmab founder dreams again of IPO of biotech company

After a sudden exit from Y-Mabs Therapeutics, Claus Møller has been quite silent for two years. Now he is building a new biotech company. Claus Møller, who helped found Genmab, has now started a new biotech adventure with Afyx Therapeutics. Claus Møller-San Pedro, who...

AFYX completes financing round of DKK 13.7M

Hørsholm, Denmark, April 15, 2024 After our recent Annual General Meeting the BOD has now in cooperation with the CEO completed an internal financing round to secure the financial basis for the transformation of our company to become an international growth and...

AFYX report from our Annual General Meeting

Hørsholm, Denmark, April 03, 2024 As of August 2023, Dr. Claus Møller-San Pedro took over as the new CEO of Inphena ApS, now a part of AFYX Therapeutics A/S. During an Extraordinary General Meeting in December 2023 our Board of Directors (BOD) was expanded to 3...